Genome-wide association meta-analysis in 652, 134 participants identifies 9 novel susceptibility loci for aortic stenosis. (25th November 2020)

• Record Type: Journal Article
• Authors: Chen, H.Y; Small, A.M; Dina, C; Cairns, B.J; Whitmer, R.A; Lathrop, M; Smith, J.G; Holm, H; Wells, Q.S; Rader, D.J; Soderberg, S; Schott, J.J; Engert, J.C; Thanassoulis, G
• Is Part Of: European heart journal. Volume 41:(2020)Supplement 2
• Publication Date: 2020-11-25
• Subjects: Valvular Heart Disease - Pathophysiology and Mechanisms; Cardiology -- Periodicals; Heart -- Diseases -- Periodicals; 616.12005
• DOI: 10.1093/ehjci/ehaa946.1862
• Languages: English
• ISSNs: 0195-668X

Abstract

Abstract: Background: Aortic stenosis (AS) is the most common form of incident valvular heart disease. While valve replacement is effective, the absence of an approved medical therapy provides no alternatives to patients with contraindications or mild disease. An improved understanding of the genetics of AS could identify targets for pharmacological intervention. Methods: An inverse variance-weighted, fixed effects meta-analysis of the association of 11, 591, 806 variants with AS was undertaken using data from 10 European cohorts totalling 652, 134 participants (13, 758 cases of AS). We queried publicly available datasets to characterize the functional consequences of genome-wide significant variants, conducted a phenome-wide association study to assess their association with other outcomes, and constructed polygenic risk scores to examine their association with AS. We also performed gene- and gene-set enrichment analyses, estimated genetic correlation with cardiovascular traits, and assessed whether five lipid or immunological biomarkers were causally associated with AS using Mendelian randomization. Results: Eighteen independent variants at 16 loci attained genome-wide significance in the meta-analysis, including variants at all seven previously reported loci. Many of the significant variants were intronic or intergenic, and the phenome-wide association study revealed extensive pleiotropy with apolipoprotein B, C-reactive protein, and other cardiovascular and immunological traits. A weighted polygenic risk score composed of the 18 variants was strongly associated with AS (adjusted OR per SD, 1.38; 95% CI, 1.33 to 1.44; p=4.6×10 –57 ), and improved the discriminatory ability for AS when added to a model that contained clinical risk factors (difference in the area under the curve p=2.0×10 –11 ). Gene-based approaches indicated higher IL6R expression in the blood among AS cases compared to controls (p=3.1×10 –6 ), and the association of LDLR with AS (p=2.3×10 –10 ). Gene set analyses revealed that genes bound by the transcription factor TCF7 or micro-RNAs miR-21, miR-219, miR-491, and miR-19 were differentially expressed in the liver depending on AS status (p≤5.7×10 –4 ), suggesting disease development may be mediated by tissue-specific transcriptional and post-transcriptional regulation. Mendelian randomization supported a causal association of five lipid and immunological biomarkers with AS, including low-density lipoprotein cholesterol (OR per mmol/L, 1.61; 95% CI, 1.48 to 1.75; p=1.3×10 –30 ). Conclusions: Evidence from large-scale genetic analyses indicate that lipid metabolism, inflammation, and calcification are key contributors to AS. Funding Acknowledgement: Type of funding source: Public Institution(s). Main funding source(s): Canadian Institutes of Health Research, National Institutes of Health